MEDP - Medpace Holdings Inc Stock Price, Fair Value and News

397.56USD-9.59 (-2.36%)Market Closed

Market Summary

USD397.56-9.59

Market Closed

-2.36%

MEDP Alerts

Big jump in Earnings (Y/Y)

1 major insider sales recently.

MEDP Stock Price

View Fullscreen

MEDP RSI Chart

MEDP Valuation

Market Cap

11.5B

Price/Earnings (Trailing)

36.88

Price/Sales (Trailing)

5.87

EV/EBITDA

28.54

Price/Free Cashflow

24.35

MEDP Price/Sales (Trailing)

MEDP Profitability

EBT Margin

18.47%

Return on Equity

46.54%

Return on Assets

17.4%

Free Cashflow Yield

4.11%

MEDP Fundamentals

MEDP Revenue

Revenue (TTM)

2.0B

Rev. Growth (Yr)

17.73%

Rev. Growth (Qtr)

2.54%

MEDP Earnings

Earnings (TTM)

312.5M

Earnings Growth (Yr)

40.74%

Earnings Growth (Qtr)

31.03%

Breaking Down MEDP Revenue

Last 7 days

5.7%

Last 30 days

-0.4%

Last 90 days

37.3%

Trailing 12 Months

117.4%

How does MEDP drawdown profile look like?

MEDP Financial Health

Current Ratio

0.78

MEDP Investor Care

Shares Dilution (1Y)

1.17%

Diluted EPS (TTM)

9.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.0B	0	0	0
2023	1.6B	1.7B	1.8B	1.9B
2022	1.2B	1.3B	1.4B	1.5B
2021	955.0M	1.0B	1.1B	1.1B
2020	891.1M	882.0M	896.1M	925.9M
2019	742.3M	786.2M	823.2M	861.0M
2018	492.6M	556.5M	625.2M	704.6M
2017	428.6M	428.9M	431.7M	436.2M
2016	374.7M	390.3M	406.0M	421.6M
2015	0	0	0	359.1M
2014	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Medpace Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	carley brian t	acquired	-	-	79.00	-
Mar 31, 2024	kraft robert o.	acquired	-	-	72.00	-
Mar 31, 2024	mccarthy cornelius p. iii	acquired	-	-	63.00	-
Mar 15, 2024	burwig susan e	sold	-41,106	403	-102	exec. vp, operations
Mar 14, 2024	keating ashley m.	sold	-102,468	409	-250	-
Mar 14, 2024	keating ashley m.	acquired	42,180	84.36	500	-
Mar 08, 2024	medpace investors, llc	sold	-10,217,800	408	-25,000	-
Mar 08, 2024	troendle august j.	sold	-10,217,800	408	-25,000	ceo
Mar 07, 2024	medpace investors, llc	sold	-30,805,500	410	-75,000	-
Mar 07, 2024	keating ashley m.	acquired	25,955	54.99	472	-

Which funds bought or sold MEDP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-22.14	135,000	5,239,000	0.04%
Apr 23, 2024	Bell Bank	reduced	-10.34	187,275	1,215,680	0.10%
Apr 23, 2024	NEW MEXICO EDUCATIONAL RETIREMENT BOARD	unchanged	-	498,000	2,061,000	0.07%
Apr 23, 2024	FirstPurpose Wealth LLC	sold off	-100	-201,697	-	-%
Apr 23, 2024	RICE HALL JAMES & ASSOCIATES, LLC	reduced	-4.51	10,134,300	49,259,800	2.81%
Apr 23, 2024	Venturi Wealth Management, LLC	unchanged	-	4,295	17,783	-%
Apr 23, 2024	DUNCKER STREETT & CO INC	new	-	129,732	129,732	0.03%
Apr 23, 2024	KLR INVESTMENT ADVISORS, LLC	sold off	-100	-342,701	-	-%
Apr 23, 2024	FIFTH THIRD BANCORP	reduced	-9.91	152,695	965,919	-%
Apr 23, 2024	Louisiana State Employees Retirement System	added	3.08	715,360	2,707,800	0.05%

Are Funds Buying or Selling MEDP?

Are funds buying MEDP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MEDP

No. of Funds

Unveiling Medpace Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 08, 2024	troendle august j.	19.4%	6,071,852	SC 13D/A
Feb 28, 2024	troendle august j.	20.8%	6,496,852	SC 13D/A
Feb 13, 2024	vanguard group inc	8.33%	2,556,443	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.9%	2,417,994	SC 13G/A
Dec 05, 2023	troendle august j.	21.9%	6,810,606	SC 13D/A
Sep 22, 2023	troendle august j.	23.0%	7,135,606	SC 13D/A
Feb 09, 2023	vanguard group inc	8.67%	2,696,146	SC 13G/A
Feb 08, 2023	wasatch advisors inc	-	0	SC 13G/A
Jan 26, 2023	blackrock inc.	10.2%	3,163,001	SC 13G/A

Recent SEC filings of Medpace Holdings Inc

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	10-Q	Quarterly Report
Apr 22, 2024	8-K	Current Report
Apr 03, 2024	ARS	ARS
Apr 03, 2024	DEF 14A	DEF 14A
Apr 03, 2024	DEFA14A	DEFA14A
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 29, 2024	8-K	Current Report
Mar 20, 2024	PRE 14A	PRE 14A

Peers (Alternatives to Medpace Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	174.4B	23.7B	-0.66%	-0.48%	39.62	7.35	-8.94%	-35.72%
IDXX	41.1B	3.7B	-6.96%	-1.95%	48.61	11.22	8.72%	24.44%
A	40.3B	6.7B	-5.62%	0.50%	32.59	5.98	-2.81%	-6.58%
DGX	15.2B	9.3B	5.76%	-6.69%	17.84	1.65	-6.38%	-9.73%
CRL	12.3B	4.1B	-11.91%	17.80%	25.9	2.98	3.86%	-2.39%
MEDP	11.5B	2.0B	-0.40%	117.42%	36.88	5.87	25.57%	21.62%
EXAS	11.5B	2.5B	2.30%	-4.05%	-56.23	4.59	19.93%	67.26%
NTRA	11.0B	1.1B	-1.39%	71.77%	-25.41	10.21	31.99%	20.63%
MID-CAP
NEOG	2.7B	929.2M	-19.07%	-29.09%	1.7K	2.89	28.93%	111.61%
GH	2.2B	563.9M	0.58%	-24.79%	-4.59	3.91	25.45%	26.76%
SMALL-CAP
CDNA	413.2M	280.3M	-13.73%	-2.49%	-2.17	1.47	-12.89%	-148.37%
ACRS	83.0M	31.2M	6.09%	-86.56%	-0.94	2.66	5.03%	-1.81%
AWH	42.0M	9.2M	-7.12%	-37.22%	-2.51	4.58	11.85%	44.12%
APDN	4.1M	9.0M	-42.00%	-72.12%	-0.56	0.45	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Medpace Holdings Inc News

Latest updates

Medpace Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	2.5%	511	498	492	461	434	394	384	351	331	309	296	278	260	260	230	205	231	230	216	214	201
Costs and Expenses	-1.0%	407	411	408	382	348	318	306	291	267	254	242	236	212	205	184	175	195	194	186	179	175
S&GA Expenses	3.7%	44.00	43.00	41.00	39.00	38.00	33.00	35.00	33.00	29.00	28.00	28.00	27.00	26.00	22.00	23.00	22.00	25.00	21.00	29.00	24.00	21.00
EBITDA Margin	3.2%	0.20*	0.19*	0.19*	0.20*	0.21*	0.21*	0.21*	0.20*	0.19*	0.19*	0.20*	0.20*	-	-	-	-	-	-	-	-	-
Income Taxes	-17.9%	10.00	12.00	13.00	15.00	13.00	5.00	16.00	13.00	4.00	6.00	6.00	3.00	5.00	4.00	6.00	6.00	8.00	6.00	5.00	7.00	5.00
Earnings Before Taxes	24.3%	113	91.00	83.00	76.00	86.00	74.00	82.00	62.00	65.00	56.00	55.00	43.00	49.00	55.00	47.00	30.00	36.00	36.00	29.00	34.00	25.00
EBT Margin	3.7%	0.18*	0.18*	0.18*	0.19*	0.19*	0.19*	0.19*	0.19*	0.18*	0.18*	0.18*	0.19*	-	-	-	-	-	-	-	-	-
Net Income	31.0%	103	78.00	71.00	61.00	73.00	69.00	66.00	49.00	61.00	50.00	49.00	40.00	43.00	51.00	41.00	24.00	29.00	30.00	24.00	27.00	19.00
Net Income Margin	6.2%	0.16*	0.15*	0.15*	0.16*	0.16*	0.17*	0.16*	0.16*	0.16*	0.16*	0.17*	0.17*	-	-	-	-	-	-	-	-	-
Free Cashflow	0.5%	147	146	106	74.00	71.00	127	101	85.00	37.00	62.00	66.00	57.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	8.4%	1,796	1,657	1,487	1,407	1,396	1,352	1,328	1,315	1,344	1,660	1,577	1,470	1,451	1,391	1,296	1,222	1,138	1,143	1,072	1,017	1,007
Current Assets	25.4%	745	594	449	379	368	334	338	329	356	691	641	550	533	474	395	319	303	317	250	194	182
Cash Equivalents	65.8%	407	245	95.00	39.00	47.00	28.00	31.00	43.00	83.00	461	398	339	333	278	219	161	134	132	79.00	20.00	30.00
Net PPE	-1.6%	119	121	115	115	114	110	105	104	99.00	93.00	88.00	86.00	85.00	85.00	71.00	66.00	50.00	47.00	44.00	40.00	38.00
Goodwill	0%	662	662	662	662	662	662	662	662	662	662	662	662	662	662	662	662	662	662	662	662	662
Liabilities	2.4%	1,124	1,098	1,016	1,016	1,048	966	979	1,032	739	707	679	618	592	585	505	484	420	417	380	359	385
Current Liabilities	3.4%	957	925	849	852	882	803	821	879	579	557	517	473	447	440	358	338	339	343	314	296	265
Short Term Borrowings	-	-	-	-	55.00	115	50.00	140	250	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56.00
Shareholder's Equity	20.1%	672	559	471	391	347	386	350	283	605	953	898	852	859	806	792	738	718	726	692	658	622
Retained Earnings	46.2%	-119	-221	-300	-371	-408	-359	-380	-446	-120	235	185	142	159	115	112	70.00	54.00	68.00	38.00	14.00	-13.14
Additional Paid-In Capital	1.5%	815	803	796	785	779	771	760	753	746	728	722	717	708	696	688	677	673	667	663	652	643
Shares Outstanding	0.8%	31.00	31.00	31.00	31.00	31.00	31.00	31.00	32.00	35.00	36.00	36.00	36.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	5,600	-	-	-	3,700	-	-	-	5,100	-	-	-	2,500	-	-	-	1,800	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-2.4%	152,677	156,395	114,385	82,518	80,076	136,684	108,491	96,619	46,256	70,894	72,353	62,761	57,319	105,498	59,763	44,267	49,148	56,940	64,292	46,630	34,005
Share Based Compensation	-16.6%	4,310	5,165	5,007	4,906	5,438	5,593	5,794	5,653	4,372	3,981	4,047	3,570	2,871	2,961	2,762	2,616	5,445	2,707	9,466	5,385	3,183
Cashflow From Investing	131.6%	2,530	-7,997	-8,662	-8,467	-9,503	-9,220	-7,187	-11,127	-11,208	-9,116	-6,600	-5,997	-9,651	-7,734	-8,643	-9,315	-5,522	-5,730	-6,132	-3,440	-3,842
Cashflow From Financing	403.0%	7,660	1,523	-49,272	-82,210	-52,683	-131,121	-109,108	-123,463	-412,083	2,431	-5,207	-50,779	9,102	-40,208	6,777	-8,406	-40,445	834	1,795	-53,519	-23,028
Buy Backs	-	-	-	-485	23,992	120,998	47,182	-	374,717	425,950	-	5,939	56,157	-	47,447	-	7,589	43,238	-	-	-	-

MEDP Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue, net (includes $12.8 million and $15.8 million with related parties for the three months ended March 31, 2024 and 2023, respectively)	$ 511,044	$ 434,074
Operating expenses:
Total direct costs	355,902	303,885
Selling, general and administrative	44,081	38,027
Depreciation	6,631	5,408
Amortization	361	550
Total operating expenses	406,975	347,870
Income from operations	104,069	86,204
Other income (expense), net:
Miscellaneous income, net	4,593	687
Interest income (expense), net	4,120	(861)
Total other income (expense), net	8,713	(174)
Income before income taxes	112,782	86,030
Income tax provision	10,191	13,136
Net income	$ 102,591	$ 72,894
Net income per share attributable to common shareholders:
Basic (in dollars per share)	$ 3.32	$ 2.35
Diluted (in dollars per share)	$ 3.20	$ 2.27
Weighted average common shares outstanding:
Basic (in shares)	30,843	31,008
Diluted (in shares)	32,001	32,155
Direct Costs
Operating expenses:
Total direct costs	$ 171,492	$ 151,068
Reimbursed out-of-pocket expenses
Operating expenses:
Total direct costs	$ 184,410	$ 152,817

MEDP Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 407,010	$ 245,449
Accounts receivable and unbilled, net (includes $1.8 million and $2.4 million with related parties at March 31, 2024 and December 31, 2023, respectively)	279,166	298,400
Prepaid expenses and other current assets (includes $0.3 million with related parties at March 31, 2024 and December 31, 2023)	58,726	49,979
Total current assets	744,902	593,828
Property and equipment, net	118,600	120,589
Operating lease right-of-use assets	138,803	144,801
Goodwill	662,396	662,396
Intangible assets, net	35,448	35,809
Deferred income taxes	75,231	74,435
Other assets	20,409	24,970
Total assets	1,795,789	1,656,828
Current liabilities:
Accounts payable (includes $2.8 million and $3.1 million with related parties at March 31, 2024 and December 31, 2023, respectively)	24,402	31,869
Accrued expenses	270,926	292,961
Advanced billings (includes $10.9 million and $10.1 million with related parties at March 31, 2024 and December 31, 2023, respectively)	616,697	559,860
Other current liabilities	44,620	40,441
Total current liabilities	956,645	925,131
Operating lease liabilities	136,156	142,122
Deferred income tax liability	2,364	2,404
Other long-term liabilities	29,082	28,221
Total liabilities	1,124,247	1,097,878
Commitments and contingencies (see Note 11)
Shareholders’ equity:
Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock - $0.01 par-value; 250,000,000 shares authorized at March 31, 2024 and December 31, 2023; $30,983,185 and 30,752,292 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	310	308
Treasury stock - $70,073 and 70,573 shares at March 31, 2024 and December 31, 2023, respectively	(12,235)	(12,322)
Additional paid-in capital	814,649	802,681
Accumulated deficit	(119,141)	(221,645)
Accumulated other comprehensive loss	(12,041)	(10,072)
Total shareholders’ equity	671,542	558,950
Total liabilities and shareholders’ equity	$ 1,795,789	$ 1,656,828

About Medpace Holdings Inc

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

CEO	Dr. August James Troendle M.D.
WEBSITE	medpace.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	5600

Medpace Holdings Inc Frequently Asked Questions

What is the ticker symbol for Medpace Holdings Inc? What does MEDP stand for in stocks?

MEDP is the stock ticker symbol of Medpace Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Medpace Holdings Inc (MEDP)?

As of Tue Apr 23 2024, market cap of Medpace Holdings Inc is 11.53 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MEDP stock?

You can check MEDP's fair value in chart for subscribers.

What is the fair value of MEDP stock?

You can check MEDP's fair value in chart for subscribers. The fair value of Medpace Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Medpace Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MEDP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Medpace Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether MEDP is over valued or under valued. Whether Medpace Holdings Inc is cheap or expensive depends on the assumptions which impact Medpace Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MEDP.

What is Medpace Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, MEDP's PE ratio (Price to Earnings) is 36.88 and Price to Sales (PS) ratio is 5.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MEDP PE ratio will change depending on the future growth rate expectations of investors.